UM CURE 2020's final aim is to bring its research results into clinical practice, both through novel treatments, and the proposal of European guidelines for UM patient management, including prognostication, follow-up and therapies.
UM CURE 2020's final aim is to bring its research results into clinical practice, both through the discovery and testing of novel treatments, and the dissemination of improved evidence-based clinical management guidelines for Uveal Melanoma.
With a project duration of 5 years, we anticipate the initiation of new clinical trials dedicated to UM metastatic patients midway through the project. The UM CURE 2020 project will lead to a better knowledge of the physiopathology of UM metastases. This is crucial to help identify potential therapeutic targets, biomarkers and appropriate surrogate endpoints to adequately evaluate treatments. Also, the involvement of pharma representatives as well as patient representatives from the start of the project should help ensure rapid translation of promising new therapeutic strategies to the clinic.
The update and dissemination of European clinical guidelines is vital for improved UM patient management across the continent. UM CURE 2020 plans to draft new guidelines for UM patient management, including prognostication, follow-up and therapies. This will be disseminated then through its communication tools and the networks of the clinicians involved in the project. The document will initially be based on the existing NICE (National Institute for Health and Care Excellence) guidelines recently published in the UK, but will include additional data and/or recommendations from the UM Cure 2020 project, also with the objective to have a broader European reach. This is likely to be finalised towards the end of the 5 year period, and will be presented at conferences for peer-review before being submitted to a clinical journal, beyond the end of the project.